Company
Headquarters: Zhubei, Taiwan
CEO: Mr. Ih-Houng Loh
TW$3.51 Billion
TWD as of Jan. 1, 2026
US$112.1 Million
| Company | Market Cap (USD) |
|---|---|
| Intuitive | $201.46 B |
| EssilorLuxottica SA | $144.43 B |
| Becton, Dickinson and Company | $55.63 B |
| HOYA Corp | $50.63 B |
| Alcon Inc. | $39.46 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
ICARES Medicus, Inc. engages in the research and development, manufacture, and sale of ophthalmic medical materials. The company provides nanomedical lubricious coatings and various surface treatments for implantable or interventional medical devices; intraocular lenses for the treatment of cataracts, myopia, hyperopia, presbyopia, or astigmatism; and related technical services. It has operations in the United States, England, Japan, Taiwan, Spain, Korea, Hungary, Israel, China, and internationally. ICARES Medicus, Inc. was incorporated in 2011 and is based in Zhubei, Taiwan.
ICARES Medicus, Inc. has the following listings and related stock indices.
Stock: TWSE: 6612